Search

Your search keyword '"Pais, Prem"' showing total 286 results
Start Over Author "Pais, Prem" Language english
286 results on '"Pais, Prem"'

3. Tobacco use and risk of acute stroke in 32 countries in the INTERSTROKE study: a case–control study

Author

Wang, Xingyu, Liu, Xin, O’Donnell, Martin J., McQueen, Matthew, Sniderman, Allan, Pare, Guillaume, Hankey, Graeme J., Rangarajan, Sumathy, Chin, Siu Lim, Rao-Melacini, Purnima, Ferguson, John, Xavier, Denis, Zhang, Hongye, Lisheng, Liu, Pais, Prem, Lopez-Jaramillo, Patricio, Damasceno, Albertino, Langhorne, Peter, Rosengren, Annika, Dans, Antonio L., Elsayed, Ahmed, Avezum, Alvaro, Mondo, Charles, Judge, Conor, Diener, Hans-Christoph, Ryglewicz, Danuta, Czlonkowska, Anna, Pogosova, Nana, Weimar, Christian, Iqbal, Romana, Diaz, Rafael, Yusoff, Khalid, Yusufali, Afzalhussein, Oguz, Aytekin, Penaherrera, Ernesto, Lanas, Fernando, Ogah, Okechukwu S., Ogunniyi, A., Iversen, Helle K., Malaga, German, Rumboldt, Zvonko, Oveisgharan, Shahram, Al Hussain, Fawaz, Nilanont, Yongchai, and Yusuf, Salim

Published
2024
Full Text
View/download PDF

5. Secondary prevention with a structured semi-interactive stroke prevention package in INDIA (SPRINT INDIA): a multicentre, randomised controlled trial

Author

Pandian, Jeyaraj Durai, Kate, Mahesh Pundlik, Sylaja, Padmavathyamma Narayanapillai, Khurana, Dheeraj, Pamidimukkala, Vijaya, Ray, Biman Kanti, Nambiar, Vivek Keshavan, Aaron, Sanjith, Mittal, Gaurav Kumar, Nagarjunakonda, Sundarachary, Pai, Aparna Ramakrishna, Gorthi, Sankar Prasad, Kumaravelu, Somasundaram, Reddy, Yerasu Muralidhar, Narayan, Sunil, Borah, Nomal Chandra, Das, Rupjyoti, Kulkarni, Girish Baburao, Huded, Vikram, Mathew, Thomas, Srivastava, M Vasantha Padma, Bhatia, Rohit, Ojha, Pawan Tarkeshwarnath, Roy, Jayanta, Abraham, Sherly Mary, Vaishnav, Anand Girish, Sharma, Arvind, Jabeen, Shaikh Afshan, Pathak, Abhishek, Bhoi, Sanjeev Kumar, Sharma, Sudhir, Sulena, Sulena, Saroja, Aralikatte Onkarappa, Ramrakhiani, Neetu, Kempegowda, Madhusudhan Byadarahalli, Sreedharan, Sapna Erat, Das, Gautam, George, Tina, Sebastian, Ivy, Sahonta, Rajeshwar, Jaiswal, Shyam Krishnakumar, Pidaparthi, Lalitha, Aghoram, Rajeshwari, Webster, Jemin Jeyachandra, Shah, Rakesh Hasmukhlal, Jha, Menka, Niak, Karkal Ravishankar, Arora, Deepti, Verma, Shweta Jain, Huilgol, Rahul, Dhasan, Aneesh, Renjith, Vishnu, Khatter, Himani, Sarma, Prabhakaran, Visakh, Sadasivan Laila, Kaur, Sukhmandeep, Rao, Tagallamudi Nagamalleswara, Dumpala, Venkatesh, Podder, Gargi, Biswas, Arindam, Rani, Karthika, Dhamodharan, Nishanthini, Sekhar, Shilpa, Chinka, Satish Kumar, Prabhu, Varsha Aroor, Zaha, Farhaz, Ramanathan, Sarvotham, Pabbu, Deepika, Choudhury, Nupur, Ramanathan, Ramya, James, Saji K, Kuthalia, Neha, Sharma, Sakshi, Gaikwad, Mayuri Ramchandra, Sen, Purbita, Basumatary, Sumita, Bhatt, Rachana Dhruvesh, Patel, Dipal, Cyriac, Mareena, Swain, Sasmita, Kumar, Narinder, Kurubara, Amaresh, Sharma, Devang, Sharma, Meenakshi, Dhaliwal, Rupinder, Murthy, Jagarlapudi Murali Krishna, Pais, Prem, Xavier, Denis, Satishchandra, Parthasarathy, Kaul, Subash, Sreenivas, Vishnubhatla, Chandran, Suresh, Calton, Rajneesh Kumar, and George, Jacob

Published
2023
Full Text
View/download PDF

7. External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry

Author

Abtan, Jeremie, Bhatt, Deepak L., Elbez, Yedid, Ducrocq, Gregory, Goto, Shinya, Smith, Sidney C., Jr, Ohman, E. Magnus, Eagle, Kim A., Fox, Kim, Harrington, Robert A., Leiter, Lawrence A., Mehta, Shamir R., Simon, Tabassome, Petrov, Ivo, Sinnaeve, Peter R., Pais, Prem, Lev, Eli, Bueno, Héctor, Wilson, Peter, and Steg, Philippe Gabriel

Published
2023
Full Text
View/download PDF

8. Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial

Author

Eikelboom, John W, Jolly, Sanjit S, Belley-Cote, Emilie P, Whitlock, Richard P, Rangarajan, Sumathy, Xu, Lizhen, Heenan, Laura, Bangdiwala, Shrikant I, Tarhuni, Wadea M, Hassany, Mohamed, Kontsevaya, Anna, Harper, William, Sharma, Sanjib Kumar, Lopez-Jaramillo, Patricio, Dans, Antonio L, Palileo-Villanueva, Lia M, Avezum, Alvaro, Pais, Prem, Xavier, Denis, Felix, Camilo, Yusufali, Afzalhussein, Lopes, Renato D, Berwanger, Otavio, Ali, Zeeshan, Wasserman, Sean, Anand, Sonia S, Bosch, Jackie, Choudhri, Shurjeel, Farkouh, Michael E, Loeb, Mark, and Yusuf, Salim

Published
2022
Full Text
View/download PDF

9. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis

Author

Joseph, Philip, Roshandel, Gholamreza, Gao, Peggy, Pais, Prem, Lonn, Eva, Xavier, Denis, Avezum, Alvaro, Zhu, Jun, Liu, Lisheng, Sliwa, Karen, Gamra, Habib, Bangdiwala, Shrikant I, Teo, Koon, Diaz, Rafael, Dans, Antonio, Lopez-Jaramillo, Patricio, Prabhakaran, Dorairaj, Castellano, Jose Maria, Fuster, Valentin, Rodgers, Anthony, Huffman, Mark D, Bosch, Jackie, Dagenais, Gilles R, Malekzadeh, Reza, and Yusuf, Salim

Published
2021
Full Text
View/download PDF

11. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

Author

Ridker, Paul M, MacFadyen, Jean G, Everett, Brendan M, Libby, Peter, Thuren, Tom, Glynn, Robert J, Kastelein, John, Koenig, Wolfgang, Genest, Jacques, Lorenzatti, Alberto, Varigos, John, Siostrzonek, Peter, Sinnaeve, Peter, Fonseca, Francisco, Nicolau, Jose, Gotcheva, Nina, Yong, Huo, Urina-Triana, Miguel, Milicic, Davor, Cifkova, Renata, Vettus, Riina, Anker, Stephan D, Manolis, Athanasios J, Wyss, Fernando, Forster, Tamas, Sigurdsson, Axel, Pais, Prem, Fucili, Alessandro, Ogawa, Hisao, Shimokawa, Hiroaki, Veze, Irina, Petrauskiene, Birute, Salvador, Leon, Cornel, Jan Hein, Klemsdal, Tor Ole, Medina, Felix, Budaj, Andrzej, Vida-Simiti, Luminita, Kobalava, Zhanna, Otasevic, Petar, Pella, Daniel, Lainscak, Mitja, Seung, Ki-Bae, Commerford, Patrick, Dellborg, Mikael, Donath, Marc, Hwang, Juey-Jen, Kultursay, Hakan, Flather, Marcus, Ballantyne, Christie, Bilazarian, Seth, Chang, William, East, Cara, Forgosh, Les, Harris, Barry, and Ligueros, Monica

Published
2018
Full Text
View/download PDF

12. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis

Author

Dagenais, Gilles R., Rydén, Lars, Leiter, Lawrence A., Lakshmanan, Mark, Dyal, Leanne, Probstfield, Jeffrey L., Atisso, Charles Messan, Shaw, Jonathan E., Conget, Ignacio, Cushman, William C., Lopez-Jaramillo, Patricio, Lanas, Fernando, Munoz, Ernesto German Cordona, Pirags, Valdis, Pogosova, Nana, Basile, Jan, Sheu, Wayne H. H., Temelkova-Kurktschiev, Theodora, Raubenheimer, Peter J., Keltai, Matyas, Hall, Stephanie, Pais, Prem, Colhoun, Helen M., Riddle, Matthew C., and Gerstein, Hertzel C.

Published
2020
Full Text
View/download PDF

13. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

Author

Ridker, Paul, Lorenzatti, Alberto, Krum, Henry, Varigos, John, Siostrzonek, Peter, Sinnaeve, Peter, Fonseca, Francisco, Nicolau, Jose, Gotcheva, Nina, Genest, Jacques, Yong, Huo, Urina-Triana, Miguel, Milicic, Davor, Cifkova, Renata, Vettus, Riina, Koenig, Wolfgang, Anker, Stephan D, Manolis, Athanasios J, Wyss, Fernando, Forster, Tamas, Sigurdsson, Axel, Pais, Prem, Fucili, Alessandro, Ogawa, Hisao, Shimokawa, Hiroaki, Veze, Irina, Petrauskiene, Birute, Salvador, Leon, Kastelein, John, Cornel, Jan Hein, Klemsdal, Tor Ole, Medina, Felix, Budaj, Andrzej, Vida-Simiti, Luminita, Kobalava, Zhanna, Otasevic, Petar, Pella, Daniel, Lainscak, Mitja, Seung, Ki-Bae, Commerford, Patrick, Dellborg, Mikael, Donath, Marc, Hwang, Juey-Jen, Kultursay, Hakan, Flather, Marcus, Ballantyne, Christie, Bilazarian, Seth, Chang, William, East, Cara, Everett, Brendan, Forgosh, Les, Glynn, Robert, Harris, Barry, Libby, Peter, Ligueros, Monica, Thuren, Tom, Bohula, Erin, Charmarthi, Bindu, Cheng, Susan, Chou, Sherry, Danik, Jacqueline, McMahon, Graham, Maron, Bradley, Ning, MingMing, Olenchock, Benjamin, Pande, Reena, Perlstein, Todd, Pradhan, Aruna, Rost, Natalia, Singhal, Aneesh, Taqueti, Viviany, Wei, Nancy, Burris, Howard, Cioffi, Angela, Dalseg, Anne Marie, Ghosh, Nilanjan, Gralow, Julie, Mayer, Tina, Rugo, Hope, Fowler, Vance, Limaye, Ajit P, Cosgrove, Sara, Levine, Donald, Lopes, Renato, Scott, John, Hilkert, Robert, Tamesby, Georgia, Mickel, Carolyn, Manning, Brian, Woelcke, Julian, Tan, Monique, Manfreda, Sheryl, Ponce, Tom, Kam, Jane, Saini, Ravinder, Banker, Kehur, Salko, Thomas, Nandy, Panjat, Tawfik, Ronda, O'Neil, Greg, Manne, Shobha, Jirvankar, Pravin, Lal, Shankar, Nema, Deepak, Jose, Jaison, Collins, Rory, Bailey, Kent, Blumenthal, Roger, Colhoun, Helen, Gersh, Bernard, Glynn, Robert J, Ridker, Paul M, MacFadyen, Jean G, and Everett, Brendan M

Published
2017
Full Text
View/download PDF

14. Resource and Infrastructure-Appropriate Management of ST-Segment Elevation Myocardial Infarction in Low- and Middle-Income Countries

Author

Chandrashekhar, Y., Alexander, Thomas, Mullasari, Ajit, Kumbhani, Dharam J., Alam, Samir, Alexanderson, Erick, Bachani, Damodar, Wilhelmus Badenhorst, Jacobus Cornelius, Baliga, Ragavendra, Bax, Jeroen J., Bhatt, Deepak L., Bossone, Eduardo, Botelho, Roberto, Chakraborthy, Rabindra Nath, Chazal, Richard A., Dhaliwal, Rupinder Singh, Gamra, Habib, Harikrishnan, Sivadasan Pillai, Jeilan, Mohamed, Kettles, David Ian, Mehta, Sameer, Mohanan, Padhinhare P., Kurt Naber, Christoph, Naik, Nitish, Ntsekhe, Mpiko, Otieno, Harun Argwings, Pais, Prem, Piñeiro, Daniel José, Prabhakaran, Dorairaj, Reddy, K. Srinath, Redha, Mustafa, Roy, Ambuj, Sharma, Meenakshi, Shor, Robert, Adriaan Snyders, Frederik, Weii Chieh Tan, Jack, Valentine, C. Michael, Wilson, B. Hadley, Yusuf, Salim, and Narula, Jagat

Published
2020
Full Text
View/download PDF

15. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study

Author

Healey, Jeff S, Oldgren, Jonas, Ezekowitz, Michael, Zhu, Jun, Pais, Prem, Wang, Jia, Commerford, Patrick, Jansky, Petr, Avezum, Alvaro, Sigamani, Alben, Damasceno, Albertino, Reilly, Paul, Grinvalds, Alex, Nakamya, Juliet, Aje, Akinyemi, Almahmeed, Wael, Moriarty, Andrew, Wallentin, Lars, Yusuf, Salim, and Connolly, Stuart J

Published
2016
Full Text
View/download PDF

16. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study

Author

O'Donnell, Martin J, Chin, Siu Lim, Rangarajan, Sumathy, Xavier, Denis, Liu, Lisheng, Zhang, Hongye, Rao-Melacini, Purnima, Zhang, Xiaohe, Pais, Prem, Agapay, Steven, Lopez-Jaramillo, Patricio, Damasceno, Albertino, Langhorne, Peter, McQueen, Matthew J, Rosengren, Annika, Dehghan, Mahshid, Hankey, Graeme J, Dans, Antonio L, Elsayed, Ahmed, Avezum, Alvaro, Mondo, Charles, Diener, Hans-Christoph, Ryglewicz, Danuta, Czlonkowska, Anna, Pogosova, Nana, Weimar, Christian, Iqbal, Romaina, Diaz, Rafael, Yusoff, Khalid, Yusufali, Afzalhussein, Oguz, Aytekin, Wang, Xingyu, Penaherrera, Ernesto, Lanas, Fernando, Ogah, Okechukwu S, Ogunniyi, Adesola, Iversen, Helle K, Malaga, German, Rumboldt, Zvonko, Oveisgharan, Shahram, Al Hussain, Fawaz, Magazi, Daliwonga, Nilanont, Yongchai, Ferguson, John, Pare, Guillaume, and Yusuf, Salim

Published
2016
Full Text
View/download PDF

17. Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics

Author

Lonn, Eva, Bosch, Jackie, Pogue, Janice, Avezum, Alvaro, Chazova, Irina, Dans, Antonio, Diaz, Rafael, Fodor, George J., Held, Claes, Jansky, Petr, Keltai, Matyas, Keltai, Katalin, Kunti, Kamlesh, Kim, Jae-Hyung, Leiter, Lawrence, Lewis, Basil, Liu, Lisheng, Lopez-Jaramillo, Patricio, Pais, Prem, Parkhomenko, Alexandr, Peters, Ron J.G., Piegas, Leopoldo S., Reid, Christopher M., Sliwa, Karen, Toff, William D., Varigos, John, Xavier, Denis, Yusoff, Khalid, Zhu, Jun, Dagenais, Gilles, and Yusuf, Salim

Published
2016
Full Text
View/download PDF

19. Tackling NCD in LMIC: Achievements and Lessons Learned From the NHLBI–UnitedHealth Global Health Centers of Excellence Program

Author

Rubinstein, Adolfo, He, Jiang, Alam, Dewan S., Peters, David H., Wu, Yangfeng, Yan, Lijing L., Merson, Michael, Ramirez, Manuel, Caballero, Benjamin, Xavier, Denis, Yusuf, Salim, Prabhakaran, Dorairaj, Narayan, K.M. Venkat, Kimaiyo, Sylvester, Velazquez, Eric, Denman, Catalina A., Cornejo, Elsa, de Zapien, Jill, Rosales, Cecilia, Miranda, J. Jaime, Gilman, Robert H., Levitt, Naomi, Gaziano, Thomas A., Ghannem, Hassen, Laatikainen, Tiina, Rabadan-Diehl, Cristina, Engelgau, Michael M., Belis, Deshiree, Sampson, Uchechukwu, Smith, Richard, Dianis, Nancy L., Wolbach, Tracy L., Matta, Gabriela, Gutierrez, Laura, Elorriaga, Natalia, Poggio, Rosana, Irazola, Vilma, Bazzano, Lydia, Bhuiya, Abbas, Wazed, Abdul, Khan, Alfazal, Siddiquee, Ali T., Islam, Anwar, Khan, Jahangir A.M., Uddin, Jasim, Hasan, Khaled, Khanam, Masuma A., Yunus, Mohammad, Chowdhury, Muhammad A.H., Monalisa, Nazratun N., Alam, Nurul, Streatfield, Peter K., Ahmed, Shyfuddin, Parvin, Sonia, Ali, Taslim, Niessen, Louis W., Hossain, Mohammad D., Koehlmoos, Tracey L.P., Standing, Hilary, Lucas, Henry, Bleich, Sara N., Anderson, Gerard F., Trujillo, Antonio J., Mirelman, Andrew J., Hao, Jesse, Zhang, Jing, Tian, Maoyi, Huang, Polly, Luo, Rong, Fang, Weigang, Li, Xian, Feng, Xiangxian, Li, Zhifang, Deal, Kelly, Peterson, Eric, DeLong, Elizabeth, Zhou, Bo, Shi, Jingpu, Neal, Bruce, Jan, Stephen, Li, Nicole, McMahon, Stephen, Zhang, Jianxin, Sun, Jixin, Elliot, Paul, Zhao, Yi, Zhang, Yuhong, Yao, Chen, Sun, Ningling Huang, Han, Qide, Shen, Ruqun, Niu, Wenyi, Wang, Yanfang, Ke, Yang, Huang, Yining, Leeder, Stephen, Lopez, Alan, Zhang, Ruijuan, Yu, Yan, Roman, Ana V., Mendoza, Carlos, Roche, Dina, Mejicano, Gabriela, Cordova, Maria A., Kroker, Maria F., Fort, Meredith, Letona, Paola, Kanter, Rebecca, Garcia, Regina, Murillo, Sandra, Chacon, Violeta, Montero, Rafael, Lopez, Erika J., Peña, Liz, Castro, Maricruz, Dengo, Ana L., Ulate, Emilce, Alvarado, Nadia, Sibrian, Josefina, Alegria, Astarte, Gutierrez, Ana M., Fontes, Flavia, Sigamani, Alben, Kamath, Deepak, Xavier, Freeda, Deepthi, K.B., Anupama, M., Mathu, Nandini, George, Nisha, Rahul, Pranjali, Pais, Prem, Girish, Preeti, Thomas, Seena, Usha, T., Thomas, Tinku, Joshi, Rajnish, Chidambaram, N., Gupta, Rajeev, Chow, Clara, Pogue, Janice, O'Donnell, Martin, Devereaux, P.J., Misquith, Dominic, Agrawal, Twinkle, Fathima, Farah N., Reddy, Kolli Srinath, Shivashankar, Roopa, Ajay, Vamadevan S., Khan, Hassan M., Kadir, M. Masood, Masood, Muhammad Q., Fatmi, Zafar, Krishnan, Anand, Singh, Kavita, Tandon, Nikhil, Khadgawat, Rajesh, Menon, V. Usha, Sethi, Bipin Kumar, Unnikrishnan, A.G., Hutcheson, Mark L., Ali, Mohammed K., Cunningham, Solveig A., Patel, Shivani A., Gujral, Unjali, Desai, Ankush, Mohan, Deepa, Pradeepa, R. Guha, Mohan, V., Viswanathan, Vijay, Sahay, Rakesh, Shah, Seema, Bantwal, Ganapathi, Varthakavi, Premlata K., Nair, Manisha, Akwanalo, Constantine, Lagat, David, Barasa, Felix, Koech, Myra, Sugut, Wilson, Korir, Belinda, Mosol, Priscah, Ali, Shamim, Sherman, Charles B., Carter, Jane, Bloomfield, Gerald, Binanay, Cynthia, Vedanthan, Rajesh, Bernabé-Ortiz, A., León-Velarde, F., Smith, George D., Málaga, Germán, García, Héctor H., Casas, Juan P., Sacksteder, Katherine, Smeeth, Liam, Huicho, Luis, Rivera, María, Gamboa, Raúl, Ebrahim, Shah, Montori, Víctor M., Wise, Robert A., Checkley, William, Diette, Gregory B., Nojilana, Beatrice, Majikela-Dlangamandla, Buyelwa, Sylvester, Carmelita, Malan, Johanna, Murphy, Katherine, Steyn, Krisela, van Niekerk, Lindi, Mash, Robert, Puoane, Thandi, Kim, Grace, Pandya, Ankur, Abrahams-Gessel, Shafika, Rhode, Hilary, Pather, Michael, Andrade, Alvaro R., Garcia, Beatriz, Velasco, Carlos, Medina, David, Bravo, Delia, Munguia, Diana, Bateman, Eric, Castro, Francisco, Schneider, Helen, Ibarra, Ilse, Zulu, Jabulisiwe, Felix, Joel, Tribe, Karla, Bobrow, Kirsten, Fairall, Lara, Folb, Naomi, Murillo, Norma, Pacheco, Norma, Rodriguez, Paloma, Navarro, Paola, Flores, Reyna, Van Zyl Smit, Richard, Meddoza, Rosario, Surka, Sameer, Van Haght, Serena, Hernandez, Yanira, Tsolekile, Lungiswa, Jeridi, Gouider, Harrabi, Imed, Maatoug, Jihen, Boughammoura, Lamia, Chaieb, Larbi, Mrizek, Nejib, Gaha, Rafika, Limam, Khalifa, Amimi, Souad, Gaha, Karima, Gamra, Habib, Al'Absi, Mustafa, Vartiainen, Erkki, Moore, Cornelius, Spillan, Debi, Cooper, Kristiane, Mitchell, Megan, Kirby, Ruth, Gao, Yunling, Aluko, Emmanuel, Sampson, Uchechukwu K., Miranda, Jaime, and Bloomfield, Gerald S.

Published
2016
Full Text
View/download PDF

20. Characteristics, clinical practice patterns, and outcomes of strokes in India: INSPIRE—A multicentre prospective study.

Author

Xavier, Denis, Murphy, Robert, Pais, Prem, Pandian, Jeyaraj, Gosala, Sarma, Mathur, Nandini, Khurana, Dheeraj, Sundararajan, R, Gupta, Rajeev, Joshi, Rajnish, Vanchilingam, Somesh, Venkatarathanamma, PN, Desai, Soaham, Reddin, Catriona, O'Donnell, Martin, and Yusuf, Salim

Subjects
PHYSICIAN practice patterns, STROKE, ISCHEMIC stroke, LONGITUDINAL method, CEREBRAL hemorrhage, ATRIAL fibrillation
Abstract

Background: India has a high burden of stroke, but there are limited data available on the characteristics of patients presenting with stroke in India. Aims: We aimed to document the clinical characteristics, practice patterns, and outcomes of patients presenting with acute stroke to Indian hospitals. Methods: A prospective registry study of patients admitted with acute clinical stroke was conducted in 62 centers across different regions in India between 2009 and 2013. Results: Of the 10,329 patients included in the prescribed registry, 71.4% had ischemic stroke, 25.2% had intracerebral hemorrhage (ICH), and 3.4% had an undetermined stroke subtype. Mean age was 60 years (SD = 14) with 19.9% younger than 50 years; 65% were male. A severe stroke at admission (modified-Rankin score 4–5) was seen in 62%, with 38.4% of patients having severe disability at discharge or dying during hospitalization. Cumulative mortality was 25% at 6 months. Neuroimaging was completed in 98%, 76% received physiotherapy, 17% speech and language therapy (SLT), 7.6% occupational therapy (OT), with variability among sites; 3.7% of ischemic stroke patients received thrombolysis. Receipt of physiotherapy (odds ratio (OR) = 0.41, 95% confidence interval (CI): 0.33–0.52) and SLT (OR = 0.45, 95% CI: 0.32–0.65) was associated with lower mortality, while a history of atrial fibrillation (OR = 2.22, 95% CI: 1.37–3.58) and ICH (OR = 2.00, 95% CI: 1.66–2.40) were associated with higher mortality. Conclusion: In the INSPIRE (In Hospital Prospective Stroke Registry) study, one-in-five patients with acute stroke was under 50 years of age, and one-quarter of stroke was ICH. There was a low provision of thrombolysis and poor access to multidisciplinary rehabilitation highlighting how improvements are needed to reduce morbidity and mortality from stroke in India. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide

Author

Gerstein, Hertzel C., Colhoun, Helen M., Dagenais, Gilles R., Diaz, Rafael, Lakshmanan, Mark, Pais, Prem, Probstfield, Jeffrey, Riddle, Matthew C., Rydén, Lars, Xavier, Denis, Atisso, Charles M., Avezum, Alvaro, Basile, Jan, Chung, Namsik, Conget, Ignacio, Cushman, William C., Franek, Edward, Hancu, Nicolae, Hanefeld, Markolf, Holt, Shaun, Jansky, Petr, Keltai, Matyas, Lanas, Fernando, Leiter, Lawrence A., Lopez‐Jaramillo, Patricio, Cardona‐Munoz, Ernesto G., Pirags, Valdis, Pogosova, Nana, Raubenheimer, Peter J., Shaw, Jonathan, Sheu, Wayne H‐H., and Temelkova‐Kurktschiev, Theodora

Published
2018
Full Text
View/download PDF

24. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Author

Ridker, Paul M, Everett, Brendan M., Thuren, Tom, MacFadyen, Jean G., Chang, William H., Ballantyne, Christie, Fonseca, Francisco, Nicolau, Jose, Koenig, Wolfgang, Anker, Stefan D., Kastelein, John J.P., Cornel, Jan H., Pais, Prem, Pella, Daniel, Genest, Jacques, Cifkova, Renata, Lorenzatti, Alberto, Forster, Tamas, Kobalava, Zhanna, Vida-Simiti, Luminita, Flather, Marcus, Shimokawa, Hiroaki, Ogawa, Hisao, Dellborg, Mikael, Rossi, Paulo R.F., Troquay, Roland P.T., Libby, Peter, and Glynn, Robert J.

Published
2017
Full Text
View/download PDF

26. Association of Lipids, Lipoproteins, and Apolipoproteins with Stroke Subtypes in an International Case Control Study (INTERSTROKE)

Author

O'Donnell, Martin J., McQueen, Matthew, Sniderman, Allan, Pare, Guillaume, Wang, Xingyu, Hankey, Graeme J., Rangarajan, Sumathy, Chin, Siu Lim, Rao-Melacini, Purnima, Ferguson, John, Xavier, Denis, Lisheng, Liu, Zhang, Hongye, Pais, Prem, Lopez-Jaramillo, Patricio, Damasceno, Albertino, Langhorne, Peter, Rosengren, Annika, Dans, Antonio L., Elsayed, Ahmed, Avezum, Alvaro, Mondo, Charles, Judge, Conor, Diener, Hans-Christoph, Ryglewicz, Danuta, Czlonkowska, Anna, Pogosova, Nana, Weimar, Christian, Iqbal, Romana, Diaz, Rafael, Yusoff, Khalid, Yusufali, Afzalhussein, Oguz, Aytekin, Penaherrera, Ernesto, Lanas, Fernando, Ogah, Okechukwu S., Ogunniyi, Adesola, Iversen, Helle K., Malaga, German, Rumboldt, Zvonko, Oveisgharan, Shahram, Al Hussain, Fawaz, Nilanont, Yongchai, Yusuf, Salim, and on Behalf of the INTERSTROKE Investigators

Subjects
Stroke, Apolipoproteins, Dyslipidemia, Lipoproteins, Medizin, lipids (amino acids, peptides, and proteins), cardiovascular diseases, Neurology (clinical), Risk factor, Case-control, Cardiology and Cardiovascular Medicine
Abstract

Background and Purpose:\ud The association of dyslipidemia with stroke has been inconsistent, which may be due to differing associations within etiological stroke subtypes. We sought to determine the association of lipoproteins and apolipoproteins within stroke subtypes.\ud Methods:\ud Standardized incident case-control STROKE study in 32 countries. Cases were patients with acute hospitalized first stroke, and matched by age, sex and site to controls. Concentrations of total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A1 (apoA1), and apoB were measured. Non-HDL-C was calculated. We estimated multivariable odds ratio (OR) and population attributable risk percentage (PAR%). Outcome measures were all stroke, ischemic stroke (and subtypes), and intracerebral hemorrhage (ICH).\ud Results:\ud Our analysis included 11,898 matched case-control pairs; 77.3% with ischemic stroke and 22.7% with ICH. Increasing apoB (OR, 1.10; 95% confidence interval [CI], 1.06 to 1.14 per standard deviation [SD]) and LDL-C (OR, 1.06; 95% CI, 1.02 to 1.10 per SD) were associated with an increase in risk of ischemic stroke, but a reduced risk of ICH. Increased apoB was significantly associated with large vessel stroke (PAR 13.4%; 95% CI, 5.6 to 28.4) and stroke of undetermined cause. Higher HDL-C (OR, 0.75; 95% CI, 0.72 to 0.78 per SD) and apoA1 (OR, 0.63; 95% CI, 0.61 to 0.66 per SD) were associated with ischemic stroke (and subtypes). While increasing HDL-C was associated with an increased risk of ICH (OR, 1.20; 95% CI, 1.14 to 1.27 per SD), apoA1 was associated with a reduced risk (OR, 0.80; 95% CI, 0.75 to 0.85 per SD). ApoB/A1 (OR, 1.38; 95% CI, 1.32 to 1.44 per SD) had a stronger magnitude of association than the ratio of LDL-C/HDL-C (OR, 1.26; 95% CI, 1.21 to 1.31 per SD) with ischemic stroke (P

Published
2022

27. The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial: Results of the Continuous Electrocardiographic Assessment Substudy

Author

Scirica, Benjamin M., Cannon, Christopher P., Emanuelsson, Håkan, Michelson, Eric L., Harrington, Robert A., Husted, Steen, James, Stefan, Katus, Hugo, Pais, Prem, Raev, Dimitar, Spinar, Jindrich, Steg, Ph. Gabriel, Storey, Robert F., and Wallentin, Lars

Published
2011
Full Text
View/download PDF

28. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease

Author

Yusuf, Salim, Lonn, Eva, Pais, Prem, Bosch, Jackie, López-Jaramillo, Patricio, Zhu, Jun, Xavier, Denis, Avezum, Alvaro, Leiter, Lawrence A., Piegas, Leopoldo S., Parkhomenko, Alexander, Keltai, Matyas, Keltai, Katalin, Sliwa, Karen, Chazova, Irina, Peters, Ron J.G., Held, Claes, Yusoff, Khalid, Lewis, Basil S., Jansky, Petr, Khunti, Kamlesh, Toff, William D., Reid, Christopher M., Varigos, John, Accini, Jose L., McKelvie, Robert, Pogue, Janice, Jung, Hyejung, Liu, Lisheng, Diaz, Rafael, Dans, Antonio, and Dagenais, Gilles

Published
2016
Full Text
View/download PDF

29. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease

Author

Lonn, Eva M., Bosch, Jackie, López-Jaramillo, Patricio, Zhu, Jun, Liu, Lisheng, Pais, Prem, Diaz, Rafael, Xavier, Denis, Sliwa, Karen, Dans, Antonio, Avezum, Alvaro, Piegas, Leopoldo S., Keltai, Katalin, Keltai, Matyas, Chazova, Irina, Peters, Ron J.G., Held, Claes, Yusoff, Khalid, Lewis, Basil S., Jansky, Petr, Parkhomenko, Alexander, Khunti, Kamlesh, Toff, William D., Reid, Christopher M., Varigos, John, Leiter, Lawrence A., Molina, Dora I., McKelvie, Robert, Pogue, Janice, Wilkinson, Joanne, Jung, Hyejung, Dagenais, Gilles, and Yusuf, Salim

Published
2016
Full Text
View/download PDF

30. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease

Author

Yusuf, Salim, Bosch, Jackie, Dagenais, Gilles, Zhu, Jun, Xavier, Denis, Liu, Lisheng, Pais, Prem, López-Jaramillo, Patricio, Leiter, Lawrence A., Dans, Antonio, Avezum, Alvaro, Piegas, Leopoldo S., Parkhomenko, Alexander, Keltai, Katalin, Keltai, Matyas, Sliwa, Karen, Peters, Ron J.G., Held, Claes, Chazova, Irina, Yusoff, Khalid, Lewis, Basil S., Jansky, Petr, Khunti, Kamlesh, Toff, William D., Reid, Christopher M., Varigos, John, Sanchez-Vallejo, Gregorio, McKelvie, Robert, Pogue, Janice, Jung, Hyejung, Gao, Peggy, Diaz, Rafael, and Lonn, Eva

Published
2016
Full Text
View/download PDF

32. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study

Author

O'Donnell, Martin J, Xavier, Denis, Liu, Lisheng, Zhang, Hongye, Chin, Siu Lim, Rao-Melacini, Purnima, Rangarajan, Sumathy, Islam, Shofiqul, Pais, Prem, McQueen, Matthew J, Mondo, Charles, Damasceno, Albertino, Lopez-Jaramillo, Patricio, Hankey, Graeme J, Dans, Antonio L, Yusoff, Khalid, Truelsen, Thomas, Diener, Hans-Christoph, Sacco, Ralph L, Ryglewicz, Danuta, Czlonkowska, Anna, Weimar, Christian, Wang, Xingyu, and Yusuf, Salim

Published
2010
Full Text
View/download PDF

35. Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND randomized trial.

Author

Branch, Kelley R.H., Dagenais, Gilles R., Avezum, Alvaro, Basile, Jan, Conget, Ignacio, Cushman, William C., Jansky, Petr, Lakshmanan, Mark, Lanas, Fernando, Leiter, Lawrence A., Pais, Prem, Pogosova, Nana, Raubenheimer, Peter J., Ryden, Lars, Shaw, Jonathan E., Sheu, Wayne H.H., Temelkova‐Kurktschiev, Theodora, Bethel, M. Angelyn, Gerstein, Hertzel C., and Chinthanie, Ramasundarahettige

Abstract

Aims: People with diabetes are at high risk for cardiovascular events including heart failure (HF). We examined the effect of the glucagon‐like peptide 1 agonist dulaglutide on incident HF events and other cardiovascular outcomes in those with or without prior HF in the randomized placebo‐controlled Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. Methods and results: The REWIND major adverse cardiovascular event (MACE) outcome was the first occurrence of a composite endpoint of non‐fatal myocardial infarction, non‐fatal stroke, or death from cardiovascular causes (including unknown causes). In this post‐hoc analysis, a HF event was defined as an adjudication‐confirmed hospitalization or urgent evaluation for HF. Of the 9901 participants studied over a median follow‐up of 5.4 years, 213/4949 (4.3%) randomly assigned to dulaglutide and 226/4952 (4.6%) participants assigned to placebo experienced a HF event (hazard ratio [HR] 0.93, 95% confidence interval [CI] 0.77–1.12; p = 0.456). In the 853 (8.6%) participants with HF at baseline, there was no change in either MACE or HF events with dulaglutide as compared to participants without HF (p = 0.44 and 0.19 for interaction, respectively). Combined cardiovascular death and HF events were marginally reduced with dulaglutide compared to placebo (HR 0.88, 95% CI 0.78–1.00; p = 0.050) but unchanged in patients with and without HF at baseline (p = 0.31). Conclusions: Dulaglutide was not associated with a reduction in HF events in patients with type 2 diabetes regardless of baseline HF status over 5.4 years of follow‐up. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

37. Polypill with or without Aspirin in Persons without Cardiovascular Disease

Author

Yusuf, Salim, Joseph, Philip, Dans, Antonio, Gao, Peggy, Teo, Koon, Xavier, Denis, Lopez-Jaramillo, Patricio, Yusoff, Khalid, Santoso, Anwar, Gamra, Habib, Talukder, Shamim, Christou, Courtney, Girish, Preeti, Yeates, Karen, Xavier, Freeda, Dagenais, Gilles, Rocha, Catalina, McCready, Tara, Tyrwhitt, Jessica, Bosch, Jackie, Pais, Prem, The International Polycap Study 3 Investigators, and Masira

Subjects
medicine.medical_specialty, Aspirin, business.industry, Cholesterol, Incidence (epidemiology), MEDLINE, General Medicine, Disease, 030204 cardiovascular system & hematology, Article, 3. Good health, law.invention, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Pharmacotherapy, Randomized controlled trial, chemistry, law, Internal medicine, medicine, 030212 general & internal medicine, Polypill, business, medicine.drug
Abstract

Digital, BACKGROUND A polypill comprising statins, multiple blood-pressure–lowering drugs, and aspirin has been proposed to reduce the risk of cardiovascular disease. METHODS Using a 2-by-2-by-2 factorial design, we randomly assigned participants without cardiovascular disease who had an elevated INTERHEART Risk Score to receive a polypill (containing 40 mg of simvastatin, 100 mg of atenolol, 25 mg of hydrochlorothiazide, and 10 mg of ramipril) or placebo daily, aspirin (75 mg) or placebo daily, and vitamin D or placebo monthly. We report here the outcomes for the polypill alone as compared with matching placebo, for aspirin alone as compared with matching placebo, and for the polypill plus aspirin as compared with double placebo. For the polypill-alone and polypill-plus-aspirin comparisons, the primary outcome was death from cardiovascular causes, myocardial infarction, stroke, resuscitated cardiac arrest, heart failure, or revascularization. For the aspirin comparison, the primary outcome was death from cardiovascular causes, myocardial infarction, or stroke. Safety was also assessed. RESULTS A total of 5713 participants underwent randomization, and the mean follow-up was 4.6 years. The low-density lipoprotein cholesterol level was lower by approximately 19 mg per deciliter and systolic blood pressure was lower by approximately 5.8 mm Hg with the polypill and with combination therapy than with placebo. The primary outcome for the polypill comparison occurred in 126 participants (4.4%) in the polypill group and in 157 (5.5%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.63 to 1.00). The primary outcome for the aspirin comparison occurred in 116 participants (4.1%) in the aspirin group and in 134 (4.7%) in the placebo group (hazard ratio, 0.86; 95% CI, 0.67 to 1.10). The primary outcome for the polypill-plus-aspirin comparison occurred in 59 participants (4.1%) in the combined-treatment group and in 83 (5.8%) in the double-placebo group (hazard ratio, 0.69; 95% CI, 0.50 to 0.97). The incidence of hypotension or dizziness was higher in groups that received the polypill than in their respective placebo groups. CONCLUSIONS Combined treatment with a polypill plus aspirin led to a lower incidence of cardiovascular events than did placebo among participants without cardiovascular disease who were at intermediate cardiovascular risk. (Funded by the Wellcome Trust and others; TIPS-3 ClinicalTrials.gov number, NCT01646437. opens in new tab.), Ciencias Médicas y de la Salud

Published
2020

38. A post hoc analysis

Author

Dagenais, Gilles R., Rydén, Lars, Leiter, Lawrence A., Lakshmanan, Mark, Dyal, Leanne, Probstfield, Jeffrey L., Atisso, Charles Messan, Shaw, Jonathan E., Conget, Ignacio, Cushman, William C., Lopez-Jaramillo, Patricio, Lanas, Fernando, Cordona Munoz, Ernesto German, Pirags, Valdis, Pogosova, Nana, Basile, Jan, Sheu, Wayne H. H., Temelkova-Kurktschiev, Theodora, Raubenheimer, Peter J., Keltai, Matyas, Hall, Stephanie, Pais, Prem, Colhoun, Helen M., Riddle, Matthew C., Gerstein, Hertzel C., and Everest

Abstract

Digital, Background The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) double blind randomized trial demonstrated that weekly subcutaneous dulaglutide 1.5 mg, a glucagon like peptide-1 receptor agonist, versus matched placebo reduced the first outcome of major adverse cardiovascular event (MACE), cardiovascular death, nonfatal myocardial infarction or nonfatal stroke (594 versus 663 events) in 9901 persons with type 2 diabetes and either chronic cardiovascular disease or risk factors, and followed during 5.4 years. These findings were based on a time-to-first-event analysis and preclude relevant information on the burden of total major events occurring during the trial. This analysis reports on the total cardiovascular or fatal events in the REWIND participants Methods We compared the total incidence of MACE or non-cardiovascular deaths, and the total incidence of expanded MACE (MACE, unstable angina, heart failure or revascularization) or non-cardiovascular deaths between participants randomized to dulaglutide and those randomized to placebo. Incidences were expressed as number per 1000 person-years. Hazard ratios (HR) were calculated using the conditional time gap and proportional means models. Results Participants had a mean age of 66.2 years, 46.3% were women and 31% had previous cardiovascular disease. During the trial there were 1972 MACE or non-cardiovascular deaths and 3673 expanded MACE or non-cardiovascular deaths. The incidence of total MACE or non-cardiovascular deaths in the dulaglutide and placebo groups was 35.8 and 40.3 per 1000 person-years, respectively [absolute reduction = 4.5 per 1000 person-years; conditional time gap HR 0.90 (95% CI, 0.82–0.98) p = 0.020, and proportional means HR 0.89 (95% CI, 0.80–0.98) p = 0.022]. The incidence of total expanded MACE or non-cardiovascular deaths in the dulaglutide and placebo groups was 67.1 and 74.7 per 1000 person-years, respectively [absolute reduction = 7.6 per 1000 person-years; conditional time gap HR 0.93 (95% CI, 0.87–0.99) p = 0.023, and proportional means HR 0.90 (95% CI, 0.82–0.99) p = 0.028]. Conclusions These findings suggest that weekly subcutaneous dulaglutide reduced total cardiovascular or fatal event burden in people with type 2 diabetes at moderate cardiovascular risk., Ciencias Médicas y de la Salud

Published
2020

39. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study

Author

Diener, Hans-Christoph, Sacco, Ralph L, Yusuf, Salim, Cotton, Daniel, Ôunpuu, Stephanie, Lawton, William A, Palesch, Yuko, Martin, Reneé H, Albers, Gregory W, Bath, Philip, Bornstein, Natan, Chan, Bernard PL, Chen, Sien-Tsong, Cunha, Luis, Dahlöf, Björn, De Keyser, Jacques, Donnan, Geoffrey A, Estol, Conrado, Gorelick, Philip, Gu, Vivian, Hermansson, Karin, Hilbrich, Lutz, Kaste, Markku, Lu, Chuanzhen, Machnig, Thomas, Pais, Prem, Roberts, Robin, Skvortsova, Veronika, Teal, Philip, Toni, Danilo, VanderMaelen, Cam, Voigt, Thor, Weber, Michael, and Yoon, Byung-Woo

Published
2008
Full Text
View/download PDF

41. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial

Author

Alexander, John H., Lopes, Renato D., Thomas, Laine, Alings, Marco, Atar, Dan, Aylward, Philip, Goto, Shinya, Hanna, Michael, Huber, Kurt, Husted, Steen, Lewis, Basil S., McMurray, John J.V., Pais, Prem, Pouleur, Hubert, Steg, Philippe Gabriel, Verheugt, Freek W.A., Wojdyla, Daniel M., Granger, Christopher B., and Wallentin, Lars

Published
2014
Full Text
View/download PDF

42. Aspirin and extended-release Dipyridamole versus Clopidogrel for recurrent stroke

Author

Yusuf, Salim, Cotton, Daniel, Ounpuu, Stephanie, Lawton, William A., Palesch, Yuko, Martin, Renee H., Albers, Gregory W., Bath, Philip, Bornstein, Natan, Chan, Bernard P.L., Sien-Tsong Chen, Cunha, Luis, Dahlof, Bjorn, De Keyser, Jacques, Donnan, Geoffrey A., Estol, Conrado, Gorelick, Philip, Gu, Vivian, Hermansson, Karin, Hilbrich, Lutz, Kaste, Markku, Chuanzhen Lu, Machnig, Thomas, Pais, Prem, Skvortsova, Veronika, and Roberts, Robin

Subjects
Aspirin -- Health aspects, Aspirin -- Usage, Stroke (Disease) -- Care and treatment, Dipyridamole -- Usage, Dipyridamole -- Health aspects, Clopidogrel -- Health aspects, Clopidogrel -- Usage
Abstract

A study attempts to evaluate the efficacy of Aspirin plus extended-release Dipyridamole against Clopidogrel in the treatment of recurrent stroke. Results conclude that both Aspirin plus extended-release Dipyridamole as well Clopidogrel were equally effective in treatment of recurrent stroke.

Published
2008

43. Telmisartan to prevent recurrent stroke and cardiovascular events

Author

Yusuf, Salim, Diener, Hans-Christoph, Sacco, Ralph L., Cotton, Daniel, Ounpuu, Stephanie, Lawton, William A., Palesch, Yuko, Martin, Renee H., Albers, Gregory W., Bath, Philip, Bornstein, Natan, Chan, Bernard P.L., Sien-Tsong Chen, Cunha, Luis, Dahlof, Bjorn, De Keyser, Jacques, Donnan, Geoffrey A., Estol, Conrado, Gorelick, Philip, Gu, Vivian, Hermansson, Karin, Kaste, Markku, Hilbrich, Lutz, Chuanzhen Lu, Machnig, Thomas, Pais, Prem, Roberts, Robin, Skvortsova, Veronika, Teal, Philip, Toni, Danilo, VanderMaelen, Carn, Voigt, Thor, Weber, Michael, and Byung-Woo Yoon

Subjects
Telmisartan -- Usage, Telmisartan -- Health aspects, Stroke (Disease) -- Prevention
Abstract

A study was conducted to evaluate the efficacy of Telmisartan as a form of treatment to prevent recurrent stroke and cardiovascular events. Results indicated that telmisartan therapy was not very effective in significantly reducing the rate of recurrent stroke, major cardiovascular events or diabetes.

Published
2008

44. Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction

Author

Diaz, Rafael, Goyal, Abhinav, Mehta, Shamir R., Afzal, Rizwan, Yusuf, Salim, Xavier, Denis, Pais, Prem, Ruda, Mikhail, Chrolavicius, Susan, Jun Zhu, Kazmi, Khawar, Lisheng Liu, Budaj, Andrej, Zubaid, Mohammad, and Avezum, Alvaro

Subjects
Dextrose -- Dosage and administration, Dextrose -- Health aspects, Glucose -- Dosage and administration, Glucose -- Health aspects, Heart attack -- Care and treatment, Insulin -- Health aspects, Insulin -- Dosage and administration, Potassium in the body -- Dosage and administration, Potassium in the body -- Health aspects, Drug therapy, Combination
Abstract

The advantages of using the glucose-insulin-potassium (GIK) therapy for patients with ST-segment elevation myocardial infarction (STEMI) are studied. GIK infusion is found to be of no significant benefit to such patients.

Published
2007

46. Dabigatran Versus Warfarin: Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation

Author

Hori, Masatsugu, Connolly, Stuart J., Zhu, Jun, Liu, Li Sheng, Lau, Chu-Pak, Pais, Prem, Xavier, Denis, Kim, Sung Soon, Omar, Razali, Dans, Antonio L., Tan, Ru San, Chen, Jyh-Hong, Tanomsup, Supachai, Watanabe, Mitsunori, Koyanagi, Masahide, Ezekowitz, Michael D., Reilly, Paul A., Wallentin, Lars, and Yusuf, Salim

Published
2013
Full Text
View/download PDF

49. Apixaban versus Warfarin in Patients with Atrial Fibrillation

Author

Granger, Christopher B., Alexander, John H., McMurray, John J.V., Lopes, Renato D., Hylek, Elaine M., Hanna, Michael, Al-Khalidi, Hussein R., Ansell, Jack, Atar, Dan, Avezum, Alvaro, Bahit, Cecilia M., Diaz, Rafael, Easton, Donald J., Ezekowitz, Justin A., Flaker, Greg, Garcia, David, Geraldes, Margarida, Gersh, Bernard J., Golitsyn, Sergey, Goto, Shinya, Hermosillo, Antonio G., Hohnloser, Stefan H., Horowitz, John, Mohan, Puneet, Jansky, Petr, Lewis, Basil S., Lopez-Sendon, Jose Luis, Pais, Prem, Parkhomenko, Alexander, Verheugt, Freek W.A., Zhu, Jun, and Wallentin, Lars

Published
2011
Full Text
View/download PDF

50. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome

Author

Alexander, John H., Lopes, Renato D., James, Stefan, Kilaru, Rakhi, He, Yaohua, Mohan, Puneet, Bhatt, Deepak L., Goodman, Shaun, Verheugt, Freek W., Flather, Marcus, Huber, Kurt, Liaw, Danny, Husted, Steen E., Lopez-Sendon, Jose, De Caterina, Raffaele, Jansky, Petr, Darius, Harald, Vinereanu, Dragos, Cornel, Jan H., Cools, Frank, Atar, Dan, Leiva-Pons, Jose Luis, Keltai, Matyas, Ogawa, Hisao, Pais, Prem, Parkhomenko, Alexander, Ruzyllo, Witold, Diaz, Rafael, White, Harvey, Ruda, Mikhail, Geraldes, Margarida, Lawrence, Jack, Harrington, Robert A., and Wallentin, Lars

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results